By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
Improving people’s quality of life
through innovative,
sustainable, and effective pain relief
Innovation in pain relief

Breaking news

View all

This is Pharmnovo

PharmNovo is a Swedish pharma company based in Medicon Village, Lund. PharmNovo has developed a novel compound portfolio based on a new type of selective delta opioid receptor agonists (DORAs), intended to provide effective neuropathic pain relief without the adverse side effects of conventional opioids. The lead candidate, PN6047, is currently in the final stages of  phase I studies and PharmNovo is preparing for phase 2 studies with PN6047 in chronic neuropathic pain and potentially other diseases of the nervous system.

Read more
A woman heaving a headache
An illustration of a brain

PN6047 – a novel drug for neuropathic pain

PN6047 is a unique substance based on research by PharmNovo’s founder Bengt von Mentzer. It is shown to be potent, safe, and effective and does not affect the receptors usually known to cause addiction to conventional opioids. It also lacks the usual unwanted side effects associated with other non-selective opioids. PN6047 will shortly be entering phase II proof-of-concept studies.

Read more

pain therapy market

Neuropathic pain affects up to ten percent of the population in Europe and the United States, but the treatment of neuropathic pain is still a clearly unmet medical need. To date, there is no pain relief offered to these patients that is not associated with potentially severe side effects.

Read more
An illustration of a brain
A woman heaving a headache

PharmNovo For investors

PharmNovo will soon initiate a phase II proof of concept clinical study of the drug candidate PN6047 to show its effect on neuropathic pain conditions.

  • New type of drug with first-in-class potential
  • Pre-clinical and clinical proof of concept
  • Experienced and dedicated team
  • Sizeable high-growth market
Read more

more news

View all
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more
September 9, 2023

Meet our new CFO!

PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO.

Read more
June 22, 2023

PharmNovo in Näringsliv

PharmNovo is featured in an article in the business magazine Affärstidningen Näringsliv. Bengt von Mentzer, Founder of PharmNovo, and Per von Mentzer, CEO of PharmNovo, tell the story of our company and our vision to change the lives of people suffering from chronic neuropathic pain.

Read more
May 2, 2023

PharmNovo attending LSX 3–4 May

PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.

Read more

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more